$7.29-9.1%Nov 13 close
The latest quarter (ended September 30, 2026) is from Pelthos Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Pelthos Therapeutics files it.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $15.4M | $7.4M | +107.87% |
| Profit | -$7.9M | -$16.2M | +51.38% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. Zelsuvmi ® (berdazimer) topical gel, 10.3%, the Company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes Xepi ® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze ® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com . Follow Pelthos on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Pelthos Therapeutics’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Pelthos Therapeutics Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From Pelthos Therapeutics Inc.'s results release of November 12, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$15.4M
+108% y/y
-1.3% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.